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ABSTRACT
Introduction: Prolactinomas represent the most common pituitary adenomas encountered in the clinic.
While a majority of these tumors will be successfully treated by dopamine agonist (DA) such as
cabergoline, their management becomes problematic since a resistance to DA can occur and/or if
the tumor displays features of aggressiveness, two conditions that are closely related.
Areas covered: Epidemiology and medical treatment of prolactinomas; resistance to DA and molecular
basis of DA-resistance; therapeutical alternatives in case of DA-resistant Prolactinomas and therapies in
development; summarizing conclusions.
Expert opinion: The management of DA-resistant prolactinomas requires a multidisciplinary approach
by an expert team. Along with discussions about surgery with or without gamma knife radiosurgery,
genetic screening for multiple endocrine neoplasia type 1 (MEN1) syndrome is actively discussed in
a case-by-case approach. In case of surgery, a careful analysis of the tumor sample can provide
information about its aggressivity potential according to recent criteria. Ultimately, temozolomide can
be indicated if the tumor is rapidly growing and/or threatening for the patient.
1. General considerations on prolactinomas
Prolactinomas represent the most common hormone-secreting
pituitary tumor encountered in the clinic with a prevalence of
100 per million of the population [1,2]. It currently accounts for
30–40% of all pituitary adenomas (PA) and, depending on their
maximal diameter, they are commonly classified into microprolac-
tinomas (<10 mm) or macroprolactinomas (≥ 10 mm).
Histopathological data previously learned us that prolactin (PRL)
can be secreted by several types of PiTNETs deriving either from
lactotrophs, somatotrophs or mammosomatotrophs cells.
Likewise, sparsely or densely granulated lactotroph tumors, acid-
ophil stem cell tumors, poorly differentiated Pit1-lineage tumors
can also lead to hyperprolactinemia. Therefore, in the following
sections wewill exclusively refer to themost common type of PRL-
secreting PiTNETs, namely the one arising from lactotroph cells
and called as Prolactinomas thereafter. Prolactinomas are over-
whelmingly diagnosed in women population with a sex ratio
estimated to be 10:1 before the fifth decade [3]. After this age,
the frequency of Prolactinomas is the same in both gender,
although macroprolactinomas are generally diagnosed at a later
age in men as compared to women (median age incidence of
51 years in men vs. 34 to 42 years in women). In children and
adolescents, PA is a rare pathological condition (less than 2% of all
intracranial tumors) and prolactinomas represent about half of the
PA phenotypes encountered in this population [4].
Because of their remarkable response-to-treatment, their slow-
growing behavior and their almost non-existent propensity to
metastasize, Prolactinomas represent the archetype of benign
tumors. In few cases however, they can present with stigmas of
aggressivity represented by either invasion of perisellar structures
(e.g. the cavernous sinus) and/or several relapse in spite of a well-
conducted treatment. Accordingly, pathologists and clinicians
adopted the terminology Pituitary Neuroendocrine Tumors
(PiTNETs) instead of PA [5].
In exceptional cases, the primitive PRL-secreting tumor
can be complicated by releasing of tumoral cells in the cere-
brospinal fluid and/or distant metastasis in the central ner-
vous system, two conditions that defined a PRL-secreting
carcinoma [6].
The clinical symptoms and complains from patients diagnosed
with microprolactinomas are usually the consequence of the
hyperprolactinemia-induced gonadotroph deficiency, namely irre-
gular menstruation or amenorrhea, decreased libido and erectile
dysfunction. These symptoms reflect the inhibitory effect exerted
by PRL on the reproductive axis by reducing both the secretion
and pulsatility of gonadotropin-releasing hormone (GnRH) neu-
rons from the hypothalamus [7,8]. The latter effect could be
mediated through inhibition of Kisspeptin neurons, which express
PRL receptors and are major regulators of GnRH neurons [9,10].
The involvement of Kisspeptin neurons have been also demon-
strated in both sexual and emotional functions which could, at
least partially, explain the decreased libido observed in patients
with hyperprolactinemia [11]. Besides irregular menstruations,
PRL-secreting PiTNETs can cause galactorrhea and be associated
with an increased risk of vertebral fractures in both men and
women [12,13].
In macroprolactinomas, symptoms at the diagnosis include
headaches, visual field impairment, symptoms related to ante-
rior pituitary deficiencies and/or hyperprolactinemia [14].
Accordingly, the aim of the therapy in patients with macro-
prolactinomas is therefore twofold:
(1) to reduce and ideally normalize the serum PRL levels.
(2) to control the tumor volume, with recovery of the visual
defect and/or pituitary functions when deficient.
The aim of this review is to summarize the current and recent
therapeutical strategies to optimize the clinical management
of difficult-to-treat macroprolactinomas.
2. The medical treatment of prolactinomas
In patients with Prolactinomas, we previously assumed that the
aim of the therapy is to restore normal gonadal functions, fertility
and to reduce tumor size [15]. DAs represent the cornerstone of
the medical treatment and are always discussed as the first-line
therapy inmicro- aswell inmacroprolactinomas [16]. Their action
is based on the property the lactotroph adenoma cells has to
express high level of the dopamine receptor subtype 2 (D2DR)
which, once binded by DA, led to the inhibition of both PRL
secretion and cell proliferation [17]. Three DA are currently avail-
able, two that are ergot-derived compounds (i.e cabergoline and
bromocriptine), and one, quinagolide, which is a non-ergot-
derived DA [18]. All of these DA are orally administered and
their efficacy in the treatment of macroprolactinomas or in case
of primary resistance to DA is briefly resumed in Table 1.
2.1. Bromocriptine
Bromocriptine (BRC) is the first DA which were used for the
treatment of Prolactinomas as its prescription started at the
end of the 80’s [19,20]. A posology ranging from 2.5 mg to
15 mg per day (median of 7.5 mg per day) is commonly used
but higher doses until 20 to 30 mg per day can be required in
almost a third of patients [21]. Results of a plethora of studies
indicate that for microprolactinomas, BRC succeeds to normal-
ize PRL levels, restores gonadal functions and decreases tumor
mass in 80–90% of patients, while similar outcomes are found
in 70% of patients with macroprolactinomas [21]. One of the
major issues of BRC is the occurrence of adverse side effects,
which can be observed in up to 10–12% of patients and
mainly represented by digestive (nausea/vomiting, constipa-
tion, reflux, pain), neurological (headaches, dizziness, confu-
sion, dyskinesia) and cardiovascular (postural hypotension,
syncope) symptoms [22,23]. They generally occur after the
initial dose and with dosage increases, but can be minimized
by introducing the drug at a low dosage (0.625 or 1.25 mg/d)
at bedtime, by taking it with food, and by very gradual dose
escalation [1]. BRC has been largely superseded by other DA
with longer lasting effects and improved side effect profiles.
Even its historical preferential use over others DA during
pregnancy is now null [24].
2.2. Cabergoline
Cabergoline (CAB) is a selective D2DR agonist which currently
represents the most efficient DA as compared to BRC and qui-
nagolide [25,26]. In a retrospective study assessing 455 cases of
hyperprolactinemia, amongst who 41% and 42% were due to
PRL-secreting micro- and macroadenomas, respectively, the PRL
excess had been normalized in a total of 86% of cases under
cabergoline treatment [27]. More specifically, the normalization
of PRL level was obtained in 77% of patients with macroprolacti-
nomas [27]. Similar results were observed in successive studies,
which, in parallel, demonstrated that CAB restored menses in
82% of women with amenorrhea [25], improved fertility by
normalizing the sperm quality and sexual function in male [28]
and eventually led to a significant tumor shrinkage in around
90% of patients with Prolactinomas [29]. Male gender, invasive
growth and giant tumors (i.e. diameter >4 cm) are associated
with a lower response to cabergoline [30–32]. A starting posol-
ogy of 0.5 mg/week is common, including in cases of macropro-
lactinomas, as the antitumor effect observed with this
compound can be both massive and rapid, as exemplified by
the occurrence of chiasmal herniation (and visual field impair-
ment) that have been described with low posologies of CAB [33].
Similarly, cases of cerebrospinal fluid rhinorrhea were described
in the weeks following the initiation of CAB when the macro-
prolactinoma invaded the sphenoidal sinus [34]. If low doses of
CAB do not normalize hyperprolactinemia and if the patient
tolerance is good, it is worthwhile to progressively increase the
dose of the drug. As such, around 60% of patients with macro-
prolactinomas will achieve a normalization of their hyperprolac-
tinemia under CAB in an average delay of less than two years
[35]. In a monocentric study, 44 patients (19.6%) received CAB
doses >2 mg/week with an average interval of 8 months
between each dose increment, and a definitive CAB resistance
diagnosed in half of the patients (21 had a partial response to
CAB with decrease but no normalization of PRL level and 1 was
unresponsive at all) [35]. Thus, increasing the dose of CAB with
periodical monitoring of both PRL levels and tumor volume
seems reasonable over a period of 24 months, before stating
that the tumor is resistant. Whether increasing the posology of
CAB can expose the patient to develop cardiac valvulopathy was
still source of uncertainty. However, a recent study showed that
for the posologies generally used in the treatment of
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Prolactinomas, the use of CAB was safe and did not overexpose
the patient to the risk of valvulopathy [36].
In conclusion, CAB is usually the first-line DA to be proposed
with a side effects profile similar to those reported for the other
DAs, but generally less frequent, less severe, and of shorter dura-
tion [37]. The only serious shortcoming currently under active
investigation is the occurrence of a compulsive behavior in 5% of
cases, such as excessive gambling and hypersexuality [38].
2.3. Quinagolide
Quinagolide (QNA) is a non-ergot-derived D2DR selective ago-
nist which led, when administrated once-daily in patients with
macroprolactinomas, to a significant reduction of tumor size
and PRL levels in around 90% of patients and a further normal-
ization of PRL level in 50% of them [39–42]. It is usually
administered at the average dose of 150 to 300 μg per day.
As compared to treatment with BRC, a greater reduction in
nausea, vomiting, dizziness, and drowsiness during QNA
administration is generally observed.
2.4. Other dopamine agonists
Pergolide is an ergot-derivated DA with long-acting D1 and D2
agonist properties, 100 times more potent than BRC allowing
effective control of hyperprolactinemia with once-daily dose.
However, it has been withdrawn from the market in 2007
because of cardiac valves adverse effects [43,44]
Lisuride is another ergot-derivated DA which was assessed
for its ability to inhibit PRL secretion [21]. However, it never
reaches the development to be used as a medical treatment in
PRL-secreting adenomas. Finally, terguride, an analog of lisur-
ide, can normalize PRL levels and reduce tumor size in a few
number of patients with microprolactinomas, however it is
currently not commercialized [20].
3. Prolactinomas resistant to dopamine agonists
The resistance-to-DA therapy represents the most challenging
condition of difficult-to-treat macroprolactinomas. It system-
atically requires a multidisciplinary approach to optimize the
care of the patient.
3.1. Definition of the resistance
The definition of resistance-to-DA still constitutes a source of
uncertainty, and multiple definitions have been proposed in the
literature. One, which is recurrent, defines the resistance as fail-
ure to achieve normal serum PRL levels under DA (commonly
admitted CAB ≥ 2 mg/week) or failure to reduce tumor size by at
least 50% from the initial volume [45] (Figure 1). The cut-off of
2 mg/week chosen on purpose for CAB resistance actually
makes sense. Indeed, in the group of patients treated with
more than ≥ 2 mg/week of CAB, only a third of them will
normalize their PRL level under 3 mg/week [46]. Therefore, the
concept of resistance-to-DA does not mean per se that it is
impossible to normalize PRL secretion but rather refers to
a state in which the usual posologies of DAs do not achieveTa
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normalization of PRL levels or significant decrease of the tumor
volume. According to these criteria, the prevalence of DA-
resistance in patients with Prolactinomas is 10 to 15% [47] .
3.2. Molecular mechanisms underlying the resistance to
DA
3.2.1. Alterations in the dopamine receptor subtype 2
(D2DR)
Most of the studies that focused on the resistance-to-DA in
Prolactinomas investigated the pattern of D2DR expression
both at the mRNA and at the protein levels (Figure 2). Our
group showed a significant decrease of the D2DR mRNA tran-
scription and identified alterations in the D2DR-related signaling
pathways of BRC-resistant human Prolactinomas, as compared to
sensitive tumors [48–51]. More recently, the differential expres-
sion of D2DR isoforms was proposed as a putative molecular
mechanism which leads to different response to DA. In the study
conducted by Shimazu et al., patients with surgically resected
Prolactinomas were divided, based on their response to DA, in
responders (n = 5), resistants (n = 5) and secondary resistants to
DA (n = 2). The authors found a significant decrease of the D2DR
long isoform mRNA expression in resistant and secondary resis-
tant tumors as compared to the sensitive ones [52]. In a similar
approach, the correlation between the D2DR gene polymorph-
isms and the response to CAB was studied in a series of 148
patients with Prolactinomas (among whom 29 males and 75
macroadenomas), however without significant results [53].
A trend for similar results was found in the study of Filopanti
et al. where the allele frequencies (i.e. the TaqI-A, TaqI-B,HphI and
NcoI alleles) of the four D2DR polymorphisms was compared
between sensitive- and resistant-to-DA Prolactinomas, without
any significant correlation eventually observed [54]. Nonetheless,
in that study, a higher frequency of the NcoI-T allele was
observed in resistant as compared to sensitive patients, which
could suggest that this variant may lead to reduction of the
expression and instability of the D2DR [54]. Recently, the whole-
exome sequencing analysis of 12 human Prolactinomas (Six
considered as responsive and six as resistant under a dose of
15 mg/day of BRC, 11/12 patients with macroprolactinomas)
revealed a differential expression of the PRDM2 (PR domain zinc
finger protein 2) gene, about five-fold lower in resistant tumors as
compared to the responsive ones [55]. The PRDM2 gene encodes
a protein whose major role is to stabilize chromosomal struc-
tures, mediates gene expression and ultimately plays a role of
tumor suppressor gene [56]. In resistant-to-DA Prolactinomas,
the expression level of the PRDM2 protein was also significantly
decreased as compared to sensitive cases and its overexpression
in the MMQ cells, a rat PRL-secreting pituitary tumor cell line, led
to the upregulation of D2DR expression and potentiated the
inhibitory effect of BRC over PRL secretion [55].
3.2.2. The TGF beta pathway
Amongst its multifunctional known roles as a cytokine, TGF beta
(TGF-β) can also regulates the proliferation of lactotroph cells as
well as their PRL secretion [57]. The TGF-β signaling cascade is
initiated by the binding of TGF-β1, TGF-β2, and TGF-β3 ligands to
the type II TGF-β receptor (TGF-β RII), followed by recruitment
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and phosphorylation of the type I TGF-β receptor (TGF-β RI) to
form a complex [58]. Once activated, TGF-β RI triggers the for-
mation of a heteromeric complex between Smad2, Smad3 and
Smad4, which ultimately translocates into the nucleus to regu-
late expression of various transcription factors [59]. Sarkar et al.
was the first to show that TGF-β1 inhibits, in a similar manner
than dopamine, both PRL secretion and proliferation of lacto-
trophs [60]. More recently, it was shown that, knocking out the
D2DR expression or using a D2DR antagonist (sulpiride) resulted
in the decrease of both TGF-β1 secretion and TGF-β RII expres-
sion by the lactotroph cells. These observations could suggest
that the inhibiting effects of dopamine could be due, at least
partially, to the TGF-β system [61]. Interestingly, in a series of 12
patients who underwent surgery because of resistance to BRC
(failure of PRL normalization after at least 3 months of
BRC ≥ 15 mg/day), a significant down-regulation of the TGF-β/
Smad signaling cascade assessed by high-content screening
techniques (qRT-PCR, western blot, immunofluorescence and
ELISA) was observed as compared to normal human anterior
pituitaries [62]. However, a comparison with DA-sensitive tumors
was unfortunately lacking in this work.
Because estradiol is known to increase PRL secretion and
sustained lactotroph proliferation, a combined treatment with
TGF-β1 and fulvestrant, a selective estrogen receptor degrader,
was tested in the rat GH3 somatolactotroph cell line. Of interest,
a significant cytotoxicity in a dose- and time-dependent manner
was observed with a simultaneous activation of Smad3 [62].
Overall, decreased TGF-β1 activity and decreased expression
of different components of the TGF-β1 system have been
described in animal models of Prolactinomas as well as in
human Prolactinomas [57]. Taking into account that TGFβ1 inhi-
bits lactotroph proliferation and PRL synthesis and secretion,
recovering local TGF-β1 activity may be one avenue worth
exploring in case of DA-resistant Prolactinomas (Figure 2).
3.2.3. Resistance-to-DA in the setting of genetic syndromes
A condition that seems to be associated with a higher risk of
resistance-to-DA is when the PRLoma developed in the set-
ting of a multiple endocrine neoplasia type 1 (MEN1) syn-
drome. The latter is a genetic disease that predisposes
carriers to development of various endocrine tumors includ-
ing PiTNETs in 30–50% of patients [63]. Prolactinomas are the
most frequent PiTNETs phenotype seen in MEN1 with 60% of
cases. Moreover, MEN1-mutated (MEN1mut) patients seem to
be less responder to DA as compared to their non-mutated
counterparts [32,64]. We are still lacking molecular explana-
tions to decipher why and how MEN1 mutations lead to
a lower sensitivity to DA; however, it is noteworthy to men-
tion that histologically, MEN1mut Prolactinomas are more
frequently invasive as compared to non-mutated
Prolactinomas [64,65]. Evolution of Prolactinomas in
MEN1mut patients are characterized by a younger age at
onset, a more aggressive behavior as reflected by a higher
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Figure 2. Schematic illustration of the main signaling pathways involved in the response to dopamine agonist therapy in pituitary lactotrophs. In the
sake of clarity, major signaling pathways are simplified and readers can refer to the review for more details. On the right side of the cell, optional therapies and the
ones that are in development are represented. The question mark means a possible effect supported by in vitro experiments.
propensity to invade surrounding structure and, in the scope
of this review, a lower sensitivity to DA [66,67].
Besides MEN1, Prolactinomas can also be developed in the
setting of a Familial Isolated Pituitary Adenomas (FIPA) syn-
drome where they represent 10% of all tumor phenotypes and
even 25% when the Arylhydrocarbon Interacting Protein (AIP)
gene is mutated [68]. In AIP-mutated Prolactinomas, 77% of
patients were male with larger tumors, less sensitive to DA as
compared to non-mutated patients [68].
3.2.4. Other molecular pathways involved in DA-resistance
Several other molecular pathways have been incriminated in the
occurrence of DA-resistance in Prolactinomas. For instance, the
expression of Filamin-A, a cytoskeleton protein with scaffolding
properties, is downregulated in parallel to the one of D2DR in
human DA-resistant Prolactinomas [69]. Moreover, silencing the
Filamin-A expression in human DA-sensitive Prolactinomas
resulted in a significant decrease of D2DR membranous expres-
sion and abrogation of the DA-induced inhibition of PRL release
and antiproliferative signals. In a reciprocal way, a restoration of
the D2DR expression and PRL responsiveness to DA occurred
when Filamin-A was overexpressed in DA-resistant
Prolactinomas [69]. Besides Filamin-A, a recent study showed
that low levels of PRB3 mRNA were observed in case of DA-
resistant Prolactinomas and exposed the patients to a higher risk
of tumor recurrence [70]. However, the exact role of the PRB3
protein in Prolactinomas remains, to date, elusive.
4. Therapeutical management of resistant-to-DA
prolactinomas
In the case of resistant-to-DA Prolactinomas, several options
can be discussed; all of them being either proposed alone,
combined and/or in a sequential approach. It includes switch
to another DA, surgery, external radiotherapy, other-than-DA
medical therapies or a watch-and-wait attitude.
4.1. Switching to another dopamine agonist
Since its commercialization, CAB is usually preferred to BRC for
the treatment of patients with Prolactinomas because of overall
greater efficacy and tolerability. However, in certain regions of
the world, BRC is still used as a first choice because of costs and/
or stock availabilities. Over the past years, CAB showed a greater
efficacy as compared to BRC for the control of PRL oversecretion
and has been successfully tested in patients considered as being
resistant to BRC [25,71–73]. Low posology of CAB could, likewise,
significantly overcome the resistance to QNA in Prolactinomas
[74], a drug which is already effective in case of BRC resistance.
However, this result could be overestimated because of better
compliance and tolerance to CAB as compared to QNA, which
actually induces a bias in the statistical analysis. In resistant-to-
CAB patient, the most commonmedical approach is therefore to
increase the dose of CAB, as long as a reduction in PRL levels can
be demonstrated with each stepwise increase [35,75]. Although
it is unlikely that patient resistant to CAB will demonstrate sensi-
tivity to BRC, there is an existing clinical report of two patients
resistant-to-CAB with micro- and macroprolactinoma, respec-
tively, who unexpectedly showed response to BRC [76].
4.2. Surgical treatment of prolactinomas
Before the development of DA, surgery was historically the treat-
ment of choice for the cure of a PRLoma [1]. Currently, indications
are mainly represented by cases of pituitary apoplexy, resistance-
to-DA or by personal choice of the patient [77]. Even in cases of
visual defect due to a macroprolactinoma, the standard of care
favors the use of DAs as compared to surgery. The visual defect
generally improves in the short term under DAs in a majority of
patients, including those with giant (i.e. maximal diameter ≥ 4 cm)
Prolactinomas and in spite of a partial antitumoral effect [31,78–
80]. However, it should be noted that there is no dedicated studies
which compared the outcome of the visual field defect in patients
with macroprolactinoma when treated by DA as compared to
patient treated in first-line by transphenoidal surgery. In highly
trained hands, selective adenomectomy results in normalization of
PRL levels in 75–90% of microprolactinomas. The multi-invasive
nature of macroprolactinomas obviously affects the rate of cure
obtained by purely surgical in such tumors which is achieved in
around 40% of cases with recurrence rates of 20% over 10 years
[81–83]. Surgery will provide the tumor histological characteristics,
especially its pathological markers of aggressivity (Ki67 and P53
immunostaining, mitotic count). A recent retrospective study ana-
lyzed the surgical outcome of 184 men with surgically
treated Prolactinomas. Among them, 178 patients had
a macroprolactinoma (152 had a maximal size below 4 cm and
26 with a maximal size >4 cm) and 61/152 (33.1%) of cases were
invasive [84]. A post-surgical initial remission of PRL levels was
observed in only 10% of invasive cases (i.e. suprasellar and/or
parasellar and/or sphenoidal invasion) [84]. In case of resistance
to DA, surgery is a valuable therapeutic option which results in
normalization of PRL in half of patients [85]. In expert pituitary
center, surgery for macroprolactinomas can be complicated by
a diabetes insipidus in around 5% of cases, cerebro-spinal-fluid
leak in 2–10% and anterior pituitary deficiencies in 1–15%, respec-
tively [82,86].
4.3. External radiotherapy
External radiotherapy is usually discusses in patients who have
clinically significant and symptomatic elevation of serum PRL in
spite of DA therapy and/or transsphenoidal surgery (which means
a third-line therapy in majority of cases). It can be proposed either
as external beam radiation therapy (conformal radiotherapy) or
stereotactic radiosurgery (SRS). Nowadays, the latter is preferably
employed as its three dimensional approach is associated with
amore rapid correction of hormone oversecretion and a lower risk
of radiation-induced neoplasms and carotid stenosis [87].
Amongst SRS, gamma knife radiosurgery (GKRS) provides
a highly conformal and selective therapeutic intervention in
a single procedure performed with image guidance and using
a multiheaded cobalt unit or a linear particle accelerator. On the
opposite, the conformal radiotherapy is characterized by several
fractions over the time (with generally daily administration). In
Prolactinomas, previous studies, including one from our group,
reported amean rate of PRL normalization ranging from 26 to 43%
with a time to remission comprised between 24 and 96 months
[88–90]. In cases of resistance/intolerance-to-DA or invasive
macroprolactinomas, a normalization of PRL level was obtained
in half of 38 patients with a mean and median prescribed doses
which were 21.3 and 25 Gy to the 50% isodose line, respectively.
These doses are the most common used for GKRS in
Prolactinomas [91]. Even if comparative studies with a significant
number of patients are lacking, there are several lines of evidence
which showed that withdrawal of DA therapy during SRS could be
associated with better outcomes in terms of endocrine remission
[89,92]. It is noteworthy to mention that cavernous sinus invasion
was shown to be a significant negative prognosticator of endo-
crine remission [92]. Finally, after 40 months, radiotherapy-
induced hypopituitarism occurred in 30% of cases.
Besides stereotactic radiotherapy, a conformal external radio-
therapy can be discussed with the risk of adverse effects which is
proportional tomaximal dose and to fractionated dose per day. As
compared to GKRS, conformal radiotherapy has two main draw-
backs: the first one is the time to remission, equals to 5–10 years
which is longer than that observed with the GKRS and therefore
requires an effective medical treatment during this period of
therapeutic latency. The second drawback of conformal radiother-
apy is the risk of side effects, including hypopituitarism (in more
than 80% of cases), optic neuritis, radiation-induced cerebral
tumors, cerebral infraction and/or cognitive dysfunctions. These
latter side effects occurred after a mean time of 10–20 years, and
were not (at least not yet) described with the use of GKRS.
The antitumor efficacy (which means stabilization and/or
decrease of the tumor residue) of radiotherapy in the setting
of Prolactinomas is high, observed in 70 to 100% of cases over
a delay ranging from 12 to 36 months [89,93]. This suggests
that GKRS could be a valid alternative treatment in cases of
intolerance or resistance-to-DA. Of note, median time to
remission was usually 20 to 40 months, which means that
gonadal steroid hormones administration can be necessary
during this period [94].
4.4. Medical treatment of DA-resistant prolactinomas
4.4.1. Temozolomide
In the setting of Prolactinomas, temozolomide (TMZ) never repre-
sents a first line treatment, however its indication can be actively
discussed when the tumor is not controlled by the usual thera-
peutic regimen (DA, surgery, radiotherapy). Its efficacy was first
demonstrated in glioblastomas before its successful use in
advanced melanomas and neuroendocrine tumors [95]. TMZ is
an alkylating chemotherapy, derivative of dacarbazine, with lipo-
philic properties allowing it to cross the blood–brain barrier and
acts by inserting a methyl group to DNA bases (mainly guanine).
By this way, it inhibits the gene transcription and cellular replica-
tion [96]. O(6)-methylguanine methyltransferase (MGMT) is an
endogenous DNA repair enzyme that can remove this methyl
group and thereby potentially counteracts the cytotoxic effect of
TMZ. An inverse correlation has been shown between the degree
of MGMT expression, due to silencing of the MGMT gene by
methylation of its promoter, and the response to TMZ treatment
in glioblastomas [97]. With 100% oral bioavailability, the standard
regimen for administering TMZ consists in an oral daily dose of
150–200 mg/m2 body surface area for 5 days every 28 days. TMZ
was proposed as a salvage therapy for the first time in 2006 to
treat a PRL-secreting pituitary carcinoma [98] and subsequently
tested in aggressive Prolactinomas [99]. In the latter and in PRL-
secreting carcinomas, an overall control of tumor growth and PRL
secretion under TMZ was observed in 66 and 73% of cases,
respectively [100]. Moreover, patients carrying aggressive
Prolactinomas who were responders to TMZ showed to have an
improved overall survival as compared to their non-responders
counterparts [101]. In our own experience, we previously reported
a remarkable efficacy of the TMZ regimen in a patient with a MEN-
1 pituitary carcinoma (Figure 3) [102] .
a. b. 
c. 
Figure 3. Coronal T1-weighted pituitary MRI in patient with a DA-resistant prolactinoma treated with temozolomide. [A] In 1995, after pituitary surgery,
showing postoperative sequellae without any large visible residual adenomatous tissue. [B] In 2006, showing a relapse of the tumor with a large adenomatous
residue in the left cavernous sinus. [C] In 2011, after 24 sessions of temozolomide (given between 2006 and 2008) with prolactin decreasing from 6950 to 98 ng/mL
and the tumor volume from 62%, at the last follow-up.
In summary, TMZ is currently a suitable therapy that can be
used as a first-line chemotherapy in case of aggressive and
DA-resistant macroprolactinomas or pituitary carcinoma with
tumor growth [103].
4.4.2. Alternative medical therapies
Other medical therapies can be discussed in a personalized
approach when the PRL-secreting PiTNET displays signs of
resistance to DAs. Somastostatinergic analogs (octreotide
and lanreotide) which bind the somatostatin receptor subtype
2 (SSTR2) are generally inefficient to inhibit PRL secretion and/
or decrease the tumor volume [104]. Nonetheless, there are
few clinical reports of DA-resistant Prolactinomas which
showed that combination of octreotide plus CAB could further
inhibit both PRL secretion and tumor volume [105,106]. We
previously hypothesized that a chimeric compound made of
SSTR2 and D2DR moieties, called dopastatin, could further
inhibit PRL secretion in SST2-overexpressing DA-resistant
Prolactinomas. Unfortunately, the inhibitory effect observed
with dopastatin was similar to the one obtained with CAB
[107]. Pasireotide (SOM230) is another somatostatin analog
with high affinity for SSTR1, 2, 3 and 5. It is currently proposed
in clinic for the treatment of acromegaly and Cushing’s disease
[18,108]. In vitro, SOM230 inhibits PRL secretion from primary
culture of human PRL-secreting PiTNETs [109,110] and was
successfully tested in a patient with DA-resistant PRLoma
[111]. In the latter, the tumor expressed high level of SSTR5,
a condition which remains exceptional in DA-resistant
Prolactinomas and explains why SOM230 is most of the time
ineffective in such cases [104]. Finally, peptide receptor radio-
nuclide therapy (PRRT) with 111In-DTPA-octreotide has shown
interesting result in a man with uncontrolled giant PRLoma
resistant to conventional therapy [112] and could, in the era of
the recent provision of 177Lu-DOTATATE (LUTHATERA®) [113],
represent an interesting treatment to discuss in specialized
center.
Two recent cases of patients with BRC-resistant Prolactinomas
suggest that metformine, an oral treatment commonly used in
type 2 diabetes, can lead to normalization of PRL level when it is
used in combination with BRC, and also to a subsequent
decrease of the tumor volume after 24 months of treatment
[114]. These results are supported in vitro by a synergistic inhibi-
tory effect of metformine and BRC in combination over tumor
growth and PRL secretion of xenograft models of lactotroph
tumors [115].
4.5. New therapeutical perspectives for DA-resistant
prolactinomas
4.5.1. The EGF/EGFR system as a potential therapeutic
target
The epidermal growth factor (EGF) system comprises several
transmembrane tyrosine kinase receptors known as EGFR
(ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4)
which, once binded by EGF, form either homo- and/or hetero-
dimers, and activation of the intrinsic kinase domain and
intracellular signaling [116]. EGFR is expressed in human
Prolactinomas even though the pattern of EGFR expression
in Prolactinomas seems to be heterogeneous and unconstant
from one tumor to another [117–119]. In experimental models,
gefitinib, an EGFR antagonist, decreased i/the cell proliferation
of the rat somatolactotrope GH3 cell line ii/the PRL mRNA
expression, iii/the PRL-secreting xenograft volume in rodents
and the PRL secretion in vivo [120]. In humans, two patients
with DA-resistant Prolactinomas were treated with lapatinib
(1,250 mg daily for 6 months), a tyrosine kinase inhibitor of
ErbB-1 and −2. One of them showed a significant improve-
ment of his PRL level (from 311 to 67 ng/ml) together with
a regression of the central portion of the tumor mass, albeit
incomplete. In the second patient, lapatinib was moderately
effective with a decrease of PRL level from 447 to 259 ng/mL
(at the last follow-up) however without any shrinkage of the
tumor mass [118].
4.5.2. The RAF/MEK/ERK and PI3K/AKT/mTOR signaling
pathways in prolactinomas
The RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways are
crucial to many aspects of cell growth and survival, in physio-
logical as well as in pathological conditions [121]. Previously,
no differences were found between PA and normal pituitary
samples in the expression of phosphorylated/total mTOR,
TSC2 or p70S6K known to be the downstream effectors of
the PI3K/AKT signaling pathway [122]. As such, the PI3K/AKT/
mTOR signaling pathway does not seem to represent
a canonical pathway involved in the pathogenesis of PA,
especially Prolactinomas. On the opposite, the expression of
the phosphorylated forms of MEK1/2 and ERK1/2, the down-
stream effectors of the MAPK signaling pathway, was signifi-
cantly higher in Prolactinomas as compared to normal
pituitaries [122]. Interestingly, a recent study suggests an intri-
cate cross-talk between the ERK and PI3K signaling pathways
in a rat somatolactotrope cell line GH4T2, in which PI3K
appears as a counterregulatory mediator of the ERK-induced
PRL transcription [123]. In the same cell line, the inhibition
effect obtained with CAB over PRL secretion and cell prolifera-
tion was mediated through the phosphorylation of S6K,
a target of mTOR which therefore seems to be closely involved
in the response to DA in Prolactinomas. Besides the response
to DA, the mTOR signaling pathway was recently identified as
a promotor of pituitary tumor development, more specifically
in Prolactinomas [124] and in vitro data suggest that rapamy-
cin, a mTOR inhibitor, could be effective in the treatment of
lactotroph tumoral cells [125]. Recently, a patient with DA-
resistant PRLoma was successfully with everolimus, a mTOR
inhibitor, with a significant decrease of both PRL levels and
tumor volume after 5 months [126]. The tumor immunohisto-
chemical analysis of this patient revealed high level of p-AKT,
p4EBP1 and p70S6K [126]. In conclusion, pharmacological
inhibitors of the ERK or PI3K pathways could constitute an
interesting therapeutic approach in DA-resistant
Prolactinomas.
5. Summarizing conclusions
In conclusion, Prolactinomas represent the most common
hormone-secreting pituitary tumor with an overrepresentation
of microadenomas in the population of young women.
Difficult-to-treat Prolactinomas are represented by
Prolactinomas that are resistant to DA therapy a condition
which is correlated to the occurrence of a macroadenoma in
more than 80% of cases [47]. Because these tumors can be
roughly assimilated to aggressive tumors, a multidisciplinary
team meeting is obviously required to guide the best thera-
peutical approach to propose [103].
The above manuscript gives an overview of the valuable
treatments to discuss when the patient does not respond
(enough) to DA. In clinical practice, two situations can be
distinguished. First presentation (which is the more frequent):
the patient keeps a significant oversecretion of PRL after
surgery, as it occurs in 60% of macroadenomas [85,127] but
the tumor does not display features of aggressivity on the
pathological analysis and does not exert a tumor mass effect
on surrounding structures. The concern is mainly related to
the effect of hyperprolactinemia, especially hypogonadism.
A step-by-step therapeutic approach is generally adopted
with increasing the dose of CAB, and potentially
a subsequent radiotherapy. In the meanwhile, an hormonal
substitution can be necessary with periodical follow up by
pituitary MRI. It is important to underline that the risk of
cardiac valvulopathy while increasing the dose of CAB is rare.
In our daily practice, we recommend, as others do, to perform
one echocardiography at baseline, which, if normal, will
require a subsequent control in the future if the patient has
an audible murmur, if he is treated for more than 5 years at
a dose of more than 3 mg per week, or for those who maintain
CAB treatment after the age of 50 years [128]. When the tumor
is aggressive according to Trouillas criteria [129], the concern
is rather related to its (uncontrolled) invasive behavior and
requires urgent therapeutic management. Repeated surgery,
MGMT immunostaining and ultimately TMZ can be proposed
with a close monitoring. Once PRL is normalized, and as long
as it remains normal or stable overtime, the likelihood of
a significant tumor growth remains low, and we therefore
assume that repeated pituitary MRI in the follow up are unne-
cessary [130].
In summary, different therapeutic modalities are discussed
during the care of a patient with a DA-resistant macroprolac-
tinoma. Selected therapeutic perspectives have been dis-
cussed and detailed in this review, but many others are in
the pipeline and could be of interest in PRL-secreting PiTNETs.
This is the case for the immunotherapy whose pharmalogical
action rather targets the microenvironment than the tumor
niche itself. A spectacular antitumoral effect of the combina-
tion of ipilimumab (anti-CTLA4) and nivolumab (Anti-PD1),
was observed in a case of ACTH-secreting pituitary carcinoma
[131]. The impact of the immune components in the patho-
genesis, behavior and response-to-treatment of Prolactinomas
remains largely unknown. Therefore, a better understanding of
the molecular and cellular factors underlying the resistance to
DA in Prolactinomas could allow in the future to personnalize
the treatment for a patient and optimize his medical care.
6. Expert opinion
Dopamine agonist (DA) treatment represents the first-line
therapy for Prolactinomas either micro- or macroadenomas
and as such, their overall efficacy is one of the most
remarkable observed in the field of medicine. Even when
a single weekly dose of CAB is unsufficient, it is worth a try
to increase the posology given the fact that a certain propor-
tion of macroprolactinomas will respond at higher than con-
ventional dose. Based on our experience, some clinical
indicators are, from the moment of the diagnosis, are already
highly predictive of resistance to DA: a (really) young age (i.e.
<18 years old) at diagnosis, the existence of a MEN1 or less
frequently AIP germline mutation, and a giant adenoma
(which means maximal diameter exceeding 4 cm). In the latter
situation, a tumor mass effect usually occurs on the optic
chiasm, likely responsible of visual field defect. The authors
want to underline that CAB therapy, even when a state of
resistance is observed with no reduction of the tumor volume,
a dramatic improvement of the visual field can be observed,
suggesting that the treatment with CAB can modify the con-
sistency of the tumor making it more soft. This hypothesis is
also supported by the possible occurrence of intratumoral
hemorrhage during the treatment with CAB.
We usually recommend a careful assessment of the DA
efficacy on both PRL secretion and tumor volume reduction
by MRI, 4 months after initiation of the therapy and then 6 to
8 months later.
As such, we recommend to wait for 12 months of treatment
under CAB before considering the tumor is resistant to DA.
The different works that have been published so far to
decipher the molecular abnormalities involved in the resis-
tance to DA in Prolactinomas have sparked many interest for
the pharmacological research however without
concrete clinical applications yet. Indeed, in the case of treat-
ing DA-resistant tumor (debulking) surgery is the prior ther-
apeutic option more or less followed by stereotactic
radiotherapy on the tumor residue. This therapeutical strategy
at least offers to the clinician the access to the tumor histo-
pathology and especially to its aggressive behavior. This last
point is important in case of multiple relapse and uncontrolled
growth of the tumor which therefore could indicate treatment
with TMZ. The results obtained on tumoral residue with
gamma knife radiosurgery (GKRS) are encouraging in
a majority of patients when performed in an expert center,
with few side effects and a prolonged control of the tumor
volume and hormonal secretion. The current alternative thera-
pies to dopamine agonist are almost nonexistent and only few
ones have shown an interesting effect in case reports. This is
the case with somatostatin analogs including pasireotide,
whose use could be attempted when the tumor expressed
high levels of somatostatin receptor subtype 5. Similarly, the
use of Lapatinib could be of interest but its efficacy has been
demonstrated in very few cases of resistant Prolactinomas.
Overall therapies directed toward membrane receptors do
not appear to us as the preferential targets to develop in
case of DA-resistant or only in a cotargeting therapeutical
approach. On the opposite, promising approach are repre-
sented by inhibitors of canonical signaling pathways situated
downstream the transmembrane receptors (e.g. MAPK) as well
as the development of epigenetic drugs that could lead to the
re-expression of D2DR when this one is down-regulated.
A subgroup of patient will present with a tumor residue of
their DA-resistant Prolactinomas however without significant
progression. As long as the tumor does not lead to tumoral
and/or hormonal symptoms, a regular follow-up can be suffi-
cient in the management of such patients. In all the remaining
cases (i.e. when a significant progression is observed over the
time) a multidisciplinary approach is of upmost importance to
discuss which therapeutical strategy presents the best risk/
benefit balance for the patient in regards to his/her clinical
profile.
We, and others, assume that the therapeutical management
of difficult to-treat macroprolactinomas will benefit, instead of
increasing the posology of DA, from identification of new ther-
apeutical targets in case of DA-resistance. As such, the recent
works conducted by the group of Melmed investigated drugs
directed against the Erb receptor as a reliable treatment to
consider. Likewise, it is worth trying to assess the efficacy of
pasireotide in tumors expressing significant level of somatosta-
tin receptor subtype 5. Finally the coming years will probably
also marked by new stereotactic radiosurgery procedures that
will undoubtedly optimize the treatment of PRLoma residues.
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